Hormone
Pharma’s wins and losses in Trump’s sprawling executive order on drug prices
Medicare, Medicare, Industry, drug price, Mediation, small molecule drugs, losses, IRA, Insulin, Prices
Back to the drawing board for Vertex’s ‘cells plus device’ diabetes programme
Vertex Pharmaceuticals, VX-264, type 1 diabetes, cell therapy, implantable device, clinical trial failure, zimislecel, insulin production
Novo Nordisk pens $2B deal for triple G agonist tied to 15% weight loss at 12 weeks
Novo Nordisk, UBT251, obesity treatment, triple agonist, weight loss, GLP-1, GIP, glucagon, The United Laboratories International Holdings Limited
Arch-backed HC Bioscience closes doors after seeing early data for tRNA asset
Vision, hydrocortisone, Bioscience
AbbVie Enters Obesity Market with $2.3 Billion Gubra Deal for Amylin Analog
AbbVie, Gubra, Obesity treatment, GUB014295 (GUBamy), Amylin analog, Weight loss drug, Pharmaceutical licensing deal
Ascletis’ Oral GLP-1 Drug Shows Promising Early Results in Obesity Treatment, Rivaling Roche’s Candidate
Ascletis Pharma, obesity treatment, oral GLP-1 receptor agonist, ASC30, weight loss, clinical trials, Roche, CT-996, pharmaceutical competition
Dual Hormone Therapies Normalize Sleep Patterns in ALS Mouse Models
Amyotrophic lateral sclerosis (ALS), sleep disturbances, orexin antagonist, melanin-concentrating hormone (MCH), suvorexant, sleep architecture, mouse models
Novo Nordisk Seeks FDA Restriction on Victoza Compounding Amid Ongoing GLP-1 Supply Issues
Novo Nordisk, FDA, Victoza, liraglutide, compounding, GLP-1, supply issues, pharmaceutical regulation
FDA Approves First Generic Version of Victoza (Liraglutide) for Type 2 Diabetes Treatment
FDA approval, generic Victoza, liraglutide, GLP-1 receptor agonist, Type 2 diabetes treatment, affordable medication options
FDA Issues Complete Response Letter for Zealand Pharma’s Glepaglutide in Short Bowel Syndrome Treatment
Zealand Pharma, Glepaglutide, GLP-2 analog, Short Bowel Syndrome (SBS), FDA rejection, Complete Response Letter